

Product Information

Cyanogen bromide-activated Matrices

C9142 (Cyanogen bromide-activated-Sepharose® 4B), C9210 (Cyanogen bromide-activated Agarose)

Product Description

Processed agarose has a primary structure consisting of alternating residues of D-galactose and 3-anhydro-galactose. These sugars provide an uncharged hydrophilic matrix. Crosslinked agarose is usually preferred over the non-crosslinked version for most affinity applications that require harsh activation or usage conditions. However, the added stability gained by crosslinking results in 30-50% loss of potential reaction sites, which are consumed in the chemistry of crosslinking.¹ The addition of crosslinks to stabilize beaded agarose does not reduce porosity significantly. Larger beads allow higher flow rates.

Cyanogen bromide (CNBr) in base reacts with hydroxyl groups on agarose to form cyanate esters or imidocarbonates, as shown in Figure 1. These groups react readily with primary amines under very mild conditions. The net result is a covalent coupling of a ligand to the agarose matrix. The preferred resultant structure is an imidocarbonate, which has no net charge. The isourea bond formed between the activated support and amine ligand is somewhat unstable, so a small but constant leakage of coupled ligand may occur. Isourea derivatives may also act as weak anion exchangers, causing nonspecific binding, especially when small ligands are immobilized.²


Cyanogen bromide-activated agarose matrices are offered for preparation of resins for affinity chromatography. CNBr-activation has various advantages:

- Many matrices contain -OH groups.
- The pH conditions needed for coupling are mild enough for many sensitive biomolecules.
- The procedure is relatively simple and reproducible.
- The coupling works for large and small ligands. However, for very small ligands, a spacer may be used to reduce steric hindrance.

These products are cyanogen bromide-activated, as CNBr itself is highly toxic and sensitive to oxidation. Most researchers prefer to use pre-activated resins rather than doing their own protocol to activate agarose with CNBr. These CNBr-activated products only need to be swollen, rinsed, and added to coupling buffer.

Figure 1.

General reaction scheme for CNBr-activation of agarose



Storage/Stability

Store these powdered products at 2-8 °C.

These CNBr-activated resins are extremely moisture-sensitive.

MERCK

Cyanogen bromide-activated Sepharose® 4B

Cat. No. C9142

- 4% agarose, 40-165 µm diameter beads
- Coupling capacity is 30-40 mg of α-chymotrypsin per mL of packed gel.

Several theses³ and dissertations⁴⁻⁶ cite use of this specific CNBr-activated Sepharose® 4B product.

Cyanogen bromide-activated Agarose

Cat. No. C9210

- 4% crosslinked agarose, 40-165 µm diameter beads
- Coupling capacity is ≥10 mg of BSA per mL of packed gel.

Several publications,⁷ theses,⁸ and dissertations⁹⁻¹² cite use of this specific CNBr-activated agarose product.

Procedure

Although numerous references¹³⁻¹⁵ can be found in the literature for use of activated agaroses with specific proteins (antibodies, enzymes, etc.) or with nucleic acids, this protocol is written for general purposes.^{16,17}

1. Dissolve the protein to be coupled in 0.1 M NaHCO₃ buffer containing 0.5 M NaCl, pH 8.3-8.5, at 5-10 mg protein per mL of gel.

Note: Other buffers can be used. However, avoid amine-containing buffers, such as Tris/Trizma®, or buffers with other nucleophiles which will react with the binding sites.

2. Wash and swell cyanogen-bromide activated resin in cold 1 mM HCl for at least 30 minutes. A total of 200 mL per gram of dry gel is added in several aliquots. Remove the supernatant, which contains lactose, by gentle filtration between successive additions.

Note: Lactose is necessary to stabilize the beads during lyophilization. However, lactose will interfere with binding if present during coupling. The use of HCl preserves the activity of the reactive groups, which hydrolyze at high pH.

3. Wash the resin with distilled water (5-10 column volumes). Then wash the resin with the NaHCO₃/NaCl coupling buffer (5 mL per gram dry gel), and **immediately** transfer to a solution of the ligand in coupling buffer.

Note: The reactive groups hydrolyze in basic solution.

4. Mix protein with gel for 2 hours at room temperature or overnight at 2-8 °C. Use a paddle stirrer or end-over-end mixer, but **not** a magnetic stir bar, which may grind the beads.
5. Wash away unreacted ligand using NaHCO₃/NaCl coupling buffer.
6. Block unreacted groups with either 0.2 M glycine or 1 M ethanolamine, pH 8.0, for 2 hours at room temperature or 16 hours at 2-8 °C.
7. Wash extensively to remove the blocking solution, first (a) with basic coupling buffer, pH ~ 8.5, then (b) with 0.1 M acetate buffer, pH 4, containing 0.5 M NaCl.
8. Complete this wash cycle of high and low pH buffer solutions four or five times.
9. If the resin is to be used immediately, equilibrate it in buffer. If not, store the resin in 1.0 M NaCl at 2-8 °C with a suitable bacteriostat.

References

1. Hermanson, G.T. *et al.*, *Immobilized Affinity Ligand Techniques*. Academic Press (New York, NY), pp. 6-9 (1992).
2. Hermanson, p. 258.
3. Sun, Yili, "Characterization of F_A/F_B-Containing Proteins PshBI and PshBII in the Photosynthetic Reaction Center of *Heliobacterium modesticaldum*". The Pennsylvania State University, M.S. thesis, p. 7 (August 2011).
4. Su, Mengna, "Development of a Specific, Sensitive, and Robust Enzyme-Linked Immunosorbent Assay (ELISA) to Detect Trace Amounts of Almond (*Prunus Dulcis* L.)". Florida State University, Ph.D. dissertation, p. 23 (2012).
5. Grindel, Brian John, "Interplay of Perlecan and MMP-7/Matrilysin Regulates Metastatic Prostate Cancer Cell Behavior: Basic and Clinical Implications". Rice University, Ph.D. dissertation, p. 35 (2015).

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

C9142,C9210pis Rev 09/21 MAM,SS,GCY

For research use only. Not for use in diagnostic procedures.



6. Sellek, Gerard Alexander, "Studies on the potential of extremozymes and extremophile biodiversity for biocatalysis". University of Bath, Ph.D. dissertation, p. 274 (2001).
7. Turapov, O. *et al.*, *Cell Rep.*, **25(1)**, 57-67.e5 (2018).
8. du Plessis, Engela Helena, "Mitigation of the Inflammatory Response to Bioprosthetic Heart Valve Tissue through Antigen-Directed Masking". University of Cape Town, M.Sc. thesis, p. 82 (February 2009).
9. Shikov, Sergei, "Structural Determinants for Heparin Binding in Human Coagulation Factor XI". Temple University, Ph.D. dissertation, p. 59 (2008).
10. Dean, Sadie, "3-Nitrotyrosine As An Indicator Of The Disease State Intermittent Claudication". Coventry University, Ph.D. dissertation, p. 119 (2009).
11. Kaiser, Gebhard Alexander, "Verbesserte *in vitro* und *in planta* DNA-Reparatur durch CPD-Photolyasen" ('Improved *in vitro* and *in planta* DNA repair through CPD photolyases'). Philipps-Universität Marburg, Dr. rer. nat. dissertation, p. 59 (2012).
12. Crisp, Peter, "Balancing the messages: RNA metabolism mediates stress-signaling and recovery in plants". Australian National University, Ph.D. dissertation, p. 128 (2016).
13. Parikh, I. *et al.*, *Methods Enzymol.*, **34**, 77-102 (1974).
14. Wilchek, M. *et al.*, *Methods Enzymol.*, **104**, 3-55 (1984).
15. Arndt-Jovin, D.J. *et al.*, *Eur. J. Biochem.*, **54(2)**, 411 (1975).
16. *Affinity Chromatography - Principles and Methods*. GE Healthcare (now Cytiva), Booklet 18-1022-29 AE (October 2007).
17. Hermanson, pp. 53-56.

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates
as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
C9142,C9210pis Rev 09/21 MAM,SS,GCY

For research use only. Not for use in diagnostic procedures.

